Santos Alba, Macías Nicolás, Vega Almudena, Abad Soraya, Linares Tania, Aragoncillo Inés, Cruzado Leonidas, Pascual Cristina, Goicoechea Marian, López-Gómez Juan Manuel
Nephrology Department, Hospital Universitario del Vinalopó, Elche, Spain.
Nephrology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Clin Kidney J. 2020 Jun 22;14(4):1120-1125. doi: 10.1093/ckj/sfaa057. eCollection 2021 Apr.
Low-molecular-weight heparins (LMWHs) are easily dialysable with high-flow membranes; however, it is not clear whether the LMWH dose should be adjusted according to the membrane type and dialysis technique. This study aimed to evaluate the influence of the dialyser on anticoagulation of the extracorporeal dialysis circuit.
Thirteen patients received the same dose of LMWH through the arterial port via three dialysis techniques: high-flux haemodialysis (HF-HD), online haemodiafiltration (HDF) and expanded haemodialysis (HDx). All dialysis was performed under similar conditions: duration, 4 h; blood flow, 400 mL/min; and dialysate flow, 500 mL/min. Antifactor Xa (aXa) activity and activated partial thromboplastin time (APTT) were measured before and after the dialysis. Clotting time of the vascular access site after haemodialysis, visual clotting score of the dialyser and any complications with the extracorporeal circuit or bleeding were registered.
Post-dialysis aXa activity in HF-HD (0.26 ± 0.02 U/mL) was significantly different from that in HDF (0.21 ± 0.02 U/mL, P = 0.024), and there was a trend in HDx (0.22 ± 0.01 U/mL, P = 0.05). APTT post-dialysis in HF-HD (30.5 ± 0.7 s) was significantly different from that in HDx (28.2 ± 0.64 s, P = 0.009) and HDF (28.8 ± 0.73 s, P = 0.009).
AXa activity in HDF was significantly lower than that in HF-HD, possibly because of more losses of LMWH through the dialyser. Given the higher anticoagulant loss in HDF and probably in HDx than in HF-HD, the enoxaparin dose administered may be adjusted according to the dialysis technique.
低分子量肝素(LMWHs)可通过高流量膜轻松透析;然而,尚不清楚LMWH剂量是否应根据膜类型和透析技术进行调整。本研究旨在评估透析器对体外透析回路抗凝的影响。
13名患者通过三种透析技术经动脉端口接受相同剂量的LMWH:高通量血液透析(HF-HD)、在线血液透析滤过(HDF)和扩展血液透析(HDx)。所有透析均在相似条件下进行:持续时间4小时;血流量400毫升/分钟;透析液流量500毫升/分钟。在透析前后测量抗Xa因子(aXa)活性和活化部分凝血活酶时间(APTT)。记录血液透析后血管通路部位的凝血时间、透析器的视觉凝血评分以及体外回路的任何并发症或出血情况。
HF-HD组透析后aXa活性(0.26±0.02 U/mL)与HDF组(0.21±0.02 U/mL,P = 0.024)有显著差异,HDx组有此趋势(0.22±0.01 U/mL,P = 0.05)。HF-HD组透析后APTT(30.5±0.7秒)与HDx组(28.2±0.64秒,P = 0.009)和HDF组(28.8±0.73秒,P = 0.009)有显著差异。
HDF组的aXa活性显著低于HF-HD组,可能是因为LMWH通过透析器的损失更多。鉴于HDF组以及可能HDx组的抗凝剂损失高于HF-HD组,可根据透析技术调整依诺肝素的给药剂量。